204 related articles for article (PubMed ID: 16817335)
1. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
2. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
3. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
6. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
Chang Y; Mbeo G; Littman SJ
J Gastrointest Cancer; 2012 Sep; 43(3):505-7. PubMed ID: 21556724
[TBL] [Abstract][Full Text] [Related]
7. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
8. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Chang PY; Cheng MF; Lee HS; Hsieh CB; Yao NS
Onkologie; 2010; 33(1-2):45-7. PubMed ID: 20164661
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.
Robinson MD; Wheatley R; Foster L; Jamdar S; Siriwardena AK; Lamarca A; Hubner R; Valle JW; McNamara MG
JCO Precis Oncol; 2024 Apr; 8():e2300572. PubMed ID: 38662981
[No Abstract] [Full Text] [Related]
11. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
Sprinzl MF; Schimanski CC; Moehler M; Schadmand-Fischer S; Galle PR; Kanzler S
BMC Cancer; 2006 Jul; 6():190. PubMed ID: 16846514
[TBL] [Abstract][Full Text] [Related]
12. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
13. Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations.
Aldecoa I; Montironi C; Vargas GM; Nunes DA; Miquel R; Cuatrecasas M
Gastroenterol Hepatol; 2019; 42(6):374-375. PubMed ID: 30293915
[No Abstract] [Full Text] [Related]
14. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Wiazzane N; Chauffert B; Ghiringhelli F
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):614-8. PubMed ID: 23711827
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas.
Paule B; Herelle MO; Rage E; Ducreux M; Adam R; Guettier C; Bralet MP
Oncology; 2007; 72(1-2):105-10. PubMed ID: 18025804
[TBL] [Abstract][Full Text] [Related]
16. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
Borbath I; Ceratti A; Verslype C; Demols A; Delaunoit T; Laurent S; Deleporte A; Vergauwe P; Van Maanen A; Sempoux C; Van Cutsem E; Van Laethem JL;
Ann Oncol; 2013 Nov; 24(11):2824-9. PubMed ID: 23975665
[TBL] [Abstract][Full Text] [Related]
17. Time to move to targeted drugs in biliary tract cancer?
Louvet C; Tournigand C
Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
[No Abstract] [Full Text] [Related]
18. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
[TBL] [Abstract][Full Text] [Related]
19. BINGO: targeted therapy for advanced biliary-tract cancer.
Valle JW
Lancet Oncol; 2014 Jul; 15(8):778-80. PubMed ID: 24852117
[No Abstract] [Full Text] [Related]
20. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
